Atopica

Purpose: 

A multi-center clinical trial evaluating the safety and efficacy of a combination of products for the treatment of allergic dermatitis in dogs

Background: 

Atopic dermatitis is a common lifelong inflammatory and pruritic skin disease in dogs. This study is a Phase IV post-approval study. It is a short term study spanning the first 28 days of therapy. Though atopy can be found in all breeds there are those more susceptible such as Terriers, Boxers, Bulldogs, Labrador Retrievers, Golden Retrievers and German Shepherds.

Inclusion criteria:

  • ≥6 months of age
  •  ≥ 2 kg
  • Adequate flea treatment that has been initiated at least 4 weeks prior to the inclusion of the dog in the study
  • Elimination diet trial completed before Day 0
  • Diagnosis of Atopic Dermatitis with at least 5 criteria from Favrot’s 2010 criteria for canine atopic dermatitis
    1. Onset of signs under 3 years of age
    2. Dog living mostly indoors
    3. Glucocorticoid-responsive pruritus
    4. Pruritus sine materia at onset (i.e. alesional pruritus)
    5. Affected front feet
    6. Affected ear pinna
    7.  Nonaffected ear margins
    8. Nonaffected dorso-lumbar area

Exclusion criteria:

  • Meet designated withdrawal times for other medications

Study Design:

  • Dogs need to be seen for 4 visits (screening visit, Day 0, Day 14 and Day 28)
  • Owners will have study forms to fill out at home on designated days throughout the study.
  • Dogs will be treated for 28 days – some dogs will be randomized to receive 3 weeks of tapering prednisolone.

Client Compensation:

  • Study covers the costs associated with the study at each visit
  • Clients that complete the study will have a credit of $250 to be used at the OSU Veterinary Medical Center

 

Contact:   Dr. Hillier (hillier [dot] 4 [at] osu [dot] edu) or Nicole Stingle (ClinicalTrials [at] cvm [dot] osu [dot] edu)